Relevant Publications

  1. Preclinical Dosimetry, Imaging, and Targeted Radionucide Therapy Studies of Lu-177-Labeled Albumin Binding PSMA-Targeted CTT1403. Ling, X.; Latoche, J.D.; Choy, C.J.; Kurland, B.F.; Laymon, C.W.; Wu, Y.; Salamacha, N.; Shen, D.; Geruntho, J.J.; Rigatti, L.H.; Windish, H.P.; Langton-Webster, B.; Berkman, C.E.; Anderson, C.J. Mol. Imaging. Biol. 2019. Jul 18. 
  2. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Behr, S.C.; Aggarwal, R.; VanBrocklin, H.F.; Flavell, R.R.; Gao, K.; Small, E.J.; Blecha, J.; Jivan, S.; Hope, T.A.; Simko, J.P.; Kurhanewicz, J.; Noworlski, S.M.; Korn, N.J.; De Los Santos, R.; Cooperberg, M.R.; Caroll, P.R.; Nguyen, H.G.; Greene, K.L.; Langton-Webster, B.; Berkman, C.E.; Seo, Y. J. Nuc Med. 2019, Jul; 60(7): 910-916.
  3. 177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Choy, C.J.; Ling, X.; Geruntho, J.J.; Beyer, S.K.; Latoche, J.D.; Langton-Webster, B.; Anderson, C.J.; Berkman, C.E. Theranostics 2017, 7, 1928.
  4. Structure-Activity Relationship of 18F-labeled phosphoramidate peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-targeted inhibitor analogues for PET imaging of prostate cancer. Dannoon, S.; Ganguly, T.; Cahaya, H.; Geruntho, J.; Galliher, M.; Beyer, S.; Choy, C.; Hopkins, M.; Regan, M.; Blecha, J.; Skultetyova, L.; Drake, C.; Jivan, S.; Barinka, C.; Jones, E.; Berkman, C.E.; VanBrocklin, H. J. Med Chem. 2016, 59, 5684
  5. A Method to Determine the Mode of Binding for Glutamate Carboxypeptidase II Inhibitors using Biolayer Interferometry.  Choy, C.J. and Berkman, C.E. J. Enz. Inhib. Med. Chem. 2016 Feb 12, 1-4 (DOI:10.3109/14756366.2015.1132208).
  6. Targeting PSMA with a 64Cu-labeled phosphoramidate inhibitor for PET/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer. Nedrow, J.R.; Day, K.E.; Latoche, J.D.; Modi, J.; Ganguly, T.; Zeng, D.; Kurland, B.F.; Berkman, C.E.; Anderson, C.J. Mol. Imaging Biol. 2016 18, 402 (doi: 10.1007/s11307-015-0908-7)
  7. A high affinity [18F]labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.  Ganguly, T.; Dannoon, S.; Hopkins, M.R.; Murphy, S.; Cahaya, H.; Blecha, J.E.; Jivan, S.; Drake, C.R.; Barinka C.; Jones, E. F.; VanBrocklin, H.F.; Berkman, C.E. Nucl. Med. Biol. 2015, 42, 780.
  8. Synthesis and Evaluation of Constrained Phosphoramidate Inhibitors of Prostate-Specific Membrane Antigen. Ley, C.R.; Beattie, N.R.; Dannoon, S.; Regan, M.; VanBrocklin, H.F.; Berkman, C.E. Bioorg. Med. Chem. Lett. 2015, 25, 2536.
  9. Development of Inhibitor-Directed Enzyme Prodrug Therapy (IDEPT) for Prostate Cancer. Martin, S.E.; Ganguly, T.; Munske, G.R.; Fulton, M.D.; Hopkins, M.R.; Berkman, C.E.; Black, M.E. Bioconjugate Chem. 2014, 25, 1752.
  10. Targeting Prostate Cancer Cells with PSMA Inhibitor-Guided Gold Nanoparticles. Kasten, B.B.; Liu, T.; Nedrow-Byers, J.R.; Benny, P.D.; Berkman, C.E. Bioorg. Med. Chem. Lett. 2013, 23, 565.
  11. PSMA-targeted SPECT agents: Mode of Binding effect on in vitro Performance.  Nedrow-Byers, J.R.; Moore, A.L.; Ganguly, T.; Hopkins, M.R.; Fulton, M.D.; Benny, P.D.; Berkman, C.E. The Prostate. 2013, 73, 355.
  12. Chemoaffinity Capture of Pre-Targeted Prostate Cancer Cells on Magnetic Beads.  Wu, L.Y.; Liu, T.; Hopkins, M.R.; Davis, W.C.; Berkman, C.E.  The Prostate 2012, 72, 1532.
  13. Targeting Prostate Cancer Cells with a Multivalent PSMA Inhibitor-Guided Streptavidin Conjugate. Liu,T.; Nedrow-Byers, J.R.; Hopkins, M.R.; Wu, L.Y.; Lee, J.; Reilly, P.T.A.; Berkman, C.E. Bioorg. Med. Chem. Lett. 2012, 22, 3931.
  14. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.  Nedrow-Byers, J.; Jewett, C.; Jabbes, M.; He, H.; Liu, T.; Benny, P.A.; Bryan, J.N.; Berkman, C.E. The Prostate. 2012, 72, 904.
  15. Spacer Length Effects on In Vitro Imaging and Surface Accessibility of Fluorescent Inhibitors of Prostate Specific Membrane Antigen. Liu, T.; Nedrow-Byers, J.R. Hopkins, M.R.; Berkman, C.E. Bioorg. Med. Chem. Lett. 2011, 21, 7013.
  16. Detection of Prostate-Specific Membrane Antigen on HUVECs in Response to Breast Tumor-Conditioned Medium. Liu, T.; Jabbes, M.; Nedrow-Byers, J.; Wu, L.Y.; Bryan, J.N.; Berkman, C.E. Int. J. Oncol. 2011, 38, 1349.
  17. Flow Cytometric Detection of Prostate Tumor Cells Using Chemoaffinity Labels. Wu, L.Y.; Liu, T.; Grimm, A.L.; Davis, W.C.; Berkman, C.E. The Prostate 2011, 71, 52.
  18. A Targeted Low Molecular Weight Near-Infrared Fluorescent Probe for Prostate Cancer. Liu, T.; Wu, L.Y.; Hopkins, M.R.; Choi, J.K.; Berkman, C.E.  Bioorg. Med. Chem. Lett. 2010, 20, 7124.
  19. Prostate Specific Membrane Antigen-Targeted Photodynamic Therapy Induces Rapid Cytoskeletal Disruption. Liu, T.; Wu, L.Y.; Berkman, C.E.  Cancer Lett. 2010, 296, 106.
  20. Targeted Photodynamic Therapy for Prostate Cancer:  Inducing Apoptosis via Activation of the Caspase-8/3 Cascade Pathway.  Liu, T.; Wu, L.Y.; Choi, J.K.; Berkman, C.E.  Int. J. Oncol. 2010, 36, 777. pdf
  21. Synthesis and in vivo evaluation of a [18F]-labeled phosphoramidate for imaging of PSMA expression.  Lapi, S.E; Wu, L.Y.; Wahnishe, H.; Pham, D.; Nedrow-Byers, J.R.; Liu, T.; VanBrocklin, H.F.; Berkman, C.E.; Jones, E.F.  J. Nuc. Med. 2009, 50, 2042.
  22. In Vitro Targeted Photodynamic Therapy with a Pyropheophorbide-a Conjugated Inhibitor of Prostate Specific Membrane Antigen.  Liu, T.; Wu, L.Y.; Choi, J.K.; Berkman, C.E.  The Prostate 2009, 69, 585. pdf
  23. Pseudoirreversible Inhibition of Prostate-Specific Membrane Antigen by Phosphoramidate Peptidomimetics. Liu, T.; Toriyabe, Y.; Kazak, M.; Berkman, C.E.  Biochemistry 2008, 47, 12658. pdf
  24. Cell-Surface Labeling and Internalization by a Fluorescent Inhibitor of Prostate-Specific Membrane Antigen.  Liu, T.; Wu, L.Y.; Kazak, M.; Berkman, C.E. The Prostate 2008, 68, 955. pdf
  25. Phosphoramidate Derivatives Of Hydroxysteriods As Inhibitors Of Prostate-Specific Membrane Antigen.  Wu, L.Y.; Do, J.; Kazak, M.; Page, H.; Toriyabe, Y. Anderson, M.O.; Berkman, C.E.  Bioorg. Med. Chem. Lett. 2008, 18, 281. pdf
  26. The Molecular Pruning of a Phosphoramidate Inhibitor of Prostate-Specific Membrane Antigen. Wu, L.Y.; Anderson, M.O.; Toriyabe, Y.; Maung, J.; Campbell, T.Y.; Tajon, C.; Kazak, M.; Moser, J.; Berkman, C.E. Bioorg. Med. Chem. 2007, 15, 7434. pdf
  27. Optimizing Phenethylphosphonamidates for the Inhibition of Prostate-Specific Membrane Antigen.  Wone, D.W.G.; Rowley, J.A.; Garofalo, A.W.; Berkman, C.E. Bioorg. Med. Chem. 2006, 14, 67. pdf
  28. Probing for a Hydrophobic a Binding Register in Prostate-Specific Membrane Antigen with Phenylalkylphosphonamidates. Maung, J.; Mallari, J.P.; Girtsman, T.A.; Wu, L.Y.; Rowley, J.A.; Santiago, N.M.; Brunelle, A.; Berkman, C.E.  Bioorg. Med. Chem. 2004, 12, 4969. pdf